Aura Biosciences, Inc. Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities
Aura Biosciences, Inc. (AURA) had Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities of $1.02 million as of 2023-12-31, per its 10-K filed 2024-03-27.
Discontinued › Notes
us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities · last filed 2024-03-27
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities $1.02M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities $517.00K.
- 2020-12-31: Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities $418.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities |
|---|---|
| 2023-12-31 | $1.02M 10-K · filed 2024-03-27 |
| 2021-12-31 | $517.00K 10-K · filed 2023-03-15 |
| 2020-12-31 | $418.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |